Therapy Directory

Docetaxel clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention. Browse Docetaxel recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1320

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Prostate Cancer
Interventions: Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 85 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Interventions: Pembrolizumab, Chemotherapy; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions: Cemiplimab, Cisplatin, Docetaxel; Drug
Lead sponsor: Krzysztof Misiukiewicz; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions: Chemotherapy (gemcitabine & docetaxel) plus BIO-11006; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pharmacokinetics of ASP9853, Non-hematologic Malignancies
Interventions: ASP9853, Docetaxel, Paclitaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Tislelizumab, Paclitaxel, Docetaxel, Irinotecan; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Detroit, Michigan • Toledo, Ohio

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Phase I and Phase II: LAE001/prednisone + afuresertib; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Cirmtuzumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions: Cryotherapy, Compression Therapy, Loose glove/sock; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Neutropenia, Breast Cancer
Interventions: Eflapegrastim, Docetaxel, Cyclophosphamide; Biological · Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Yuma, Arizona • Anaheim, California + 5 more

Conditions: Non-Small Cell Lung Cancer
Interventions: mogamulizumab, Docetaxel; Biological · Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Lafayette, Indiana • Baltimore, Maryland • Canton, Ohio + 2 more

Conditions: Advanced Solid Tumors
Interventions: GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more

About this Docetaxel clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Docetaxel.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Docetaxel clinical trials

Filter and sort this therapy

Live official records

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

About this Docetaxel clinical trials directory page